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Dear Editor,
In the spring of 2005, a female patient aged 67 years at that
time was referred to our service because of progressive
haemoglobin decline. There was no history of bleeding. In
1997, in an external institution, bone marrow aspiration and
cytogenetic analysis yielded the diagnosis of a myelodys-
platic syndrome with a 5q-minus deletion (del5q), type 5q-
minus syndrome (5q-Syn). Our laboratory tests revealed
severe anaemia (haemoglobin 5 g/dL) as well as leucopenia
[2.8×109/L (normal range, 3.7–9.6×109/L)], while overall
neutrophil and thrombocyte counts were in the normal
ranges. Given the symptomatic anaemia, erythrocyte con-
centrate transfusions were initiated. In May 2006, we
started oral therapy with lenalidomide (10 mg/day for
21 days; 28-day cycle). Already by mid-July 2006, the
patient had reached a haemoglobin value of 12 g/dL
(Fig. 1). Until October 2006, four lenalidomide cycles were
administered in total. Except for transient neutropenia grade
III, no other side effects were recorded. Follow-up bone
marrow examination in November 2006 revealed haemato-
logical and a borderline cytogenetic remission (“borderline”
because only 18 metaphases were analysed and not 20 as
postulated by List [1]). Lenalidomide therapy was not
restarted. In further bone marrow examinations, the
reappearance of the del5q (March 2007, 18/79 metaphases
(23%); March 2008, 8/20 (40%) metaphases) was detected.
Nevertheless, 26 months after treatment cessation, there is
still no evidence of anaemia or cytopenia in peripheral
blood and no change in mean cellular volume.
This is—to our knowledge—the first long-term follow-up
of a patient with a 5q-Syn having achieved haematological
and borderline cytogenetic remission under lenalidomide,
who then ceased therapy. In few other cases published,
lenalidomide was stopped because of drug intolerance and
before the patients achieved haematological remission [2]. In
our case, lenalidomide was paused because of beginning
polyglobulia—a well-known adverse effect of lenalidomide
[3]. Furthermore, the current expert recommendations to
continue treatment after achieving haematological remission
[4] did not exist yet.
The therapeutic mechanism of action of lenalidomide is
matter of speculation. It has been suggested that lenalido-
mide exerts a del5q cytotoxic effect [1, 5] and an
immunomodulating effect, which could have a positive
effect on bone marrow microenvironment and therefore on
haematopoiesis [2, 6]. Accounting for these possible
mechanisms of action, the direct cytotoxic effect of
lenalidomide gives us an explanation for the rapid
reappearance of del5q clone. Treatment discontinuation
with achievement of borderline cytogenetic remission
appears to be too short for long-term suppression of the
del5q clone, probably because of the incomplete elimina-
tion of CD34 del5q-progenitor cells, insofar as complete
elimination is possible [7]. However, it is noteworthy that
our patient has not suffered haematological relapse for more
than 26 months since discontinuing treatment, despite the
rapid reappearance of the 5q-minus clone. We believe that
the microenvironmental effect of lenalidomide may prolong
the time interval between cytogenetic and haematologic
relapse in 5q-Syn, at least for some patients. This
phenomenon would be an argument against a continuous
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lenalidomide therapy, which is associated with possible
adverse effects and enormous costs.
Glossary of abbreviations
Granulo Granulocytes
Hb Haemoglobin
del5q 5q-minus deletion
5q-Syn 5q-minus syndrome
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Fig. 1 Complete haematologi-
cal remission was still evident
26 months after lenalidomide
discontinuation
106 Ann Hematol (2010) 89:105–106
